New drug combination for hard-to-treat Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two immunotherapy drugs (IMM01 and tislelizumab) compared with standard chemotherapy for people with classical Hodgkin lymphoma that has not responded to PD-1/PD-L1 inhibitors. The goal is to see if this new approach can help when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have classical Hodgkin lymphoma, confirmed by a biopsy.
- Your lymphoma must have stopped responding to or worsened after treatment with a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab).
- You need to have already tried other standard treatments that have not worked.
- Your blood cell counts, liver, and kidney function must be good enough to receive the study treatment.
- You cannot have cancer that has spread to the brain or spinal cord.
- You must not have received chemotherapy or other systemic cancer therapy within 4 weeks before starting the trial.
- You cannot have HIV, active autoimmune disease that required systemic treatment in the last 2 years, or severe allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy drug called an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to at least two previous treatments. It may be an option if you cannot have or do not want a stem cell transplant.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
This trial combines an immunotherapy drug (a type of treatment that helps your immune system fight cancer) with radiation therapy for people with early-stage classic Hodgkin lymphoma. The goal is to see if this combination can treat the cancer effectively while possibly reducing side effects.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.